- Home
- Publications
- Publication Search
- Publication Details
Title
Olaparib for the treatment of breast cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 6, Pages 751-759
Publisher
Informa UK Limited
Online
2017-04-11
DOI
10.1080/13543784.2017.1318847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.
- (2017) L. R. Molife et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Olaparib for the treatment of epithelial ovarian cancer
- (2016) Jennifer McLachlan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- (2016) Jonathan A Ledermann et al. LANCET ONCOLOGY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
- (2016) Philip C. Schouten et al. Trials
- Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
- (2015) Christopher J. Lord et al. Annual Review of Medicine
- Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
- (2015) Ruud van der Noll et al. BRITISH JOURNAL OF CANCER
- Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
- (2015) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Advances in PARP inhibitors for the treatment of breast cancer
- (2015) Omer Dizdar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
- (2015) J. Watkins et al. Cancer Discovery
- Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
- (2015) Pradip De et al. NEOPLASIA
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
- (2014) J. Balmaña et al. ANNALS OF ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Ann H. Partridge et al. JOURNAL OF CLINICAL ONCOLOGY
- Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
- (2014) M. Bonotto et al. ONCOLOGIST
- "The Race" to Clone BRCA1
- (2014) M.-C. King SCIENCE
- Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention
- (2014) F. J. Couch et al. SCIENCE
- A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation-Driven Colorectal Tumor Growth
- (2013) T. Lau et al. CANCER RESEARCH
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- Appraising iniparib, the PARP inhibitor that never was—what must we learn?
- (2013) Joaquin Mateo et al. Nature Reviews Clinical Oncology
- Resistance to PARP-Inhibitors in Cancer Therapy
- (2013) Alicia Montoni et al. Frontiers in Pharmacology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
- (2012) Jenna L. Riffell et al. NATURE REVIEWS DRUG DISCOVERY
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
- (2010) Alan D. D'Andrea NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now